EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia

So Inamura, Yusuke Fukiage, Hisato Kobayashi, Manami Tsutsumiuchi, Masaya Seki, Minekatsu Taga, Masato Fukushima, Motohiro Kobayashi, Osamu Yokoyama, Naoki Terada iD

International Journal of Urology · 2025

DOI: 10.1111/iju.15612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von So Inamura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, 5-alpha Reductase Inhibitors, Azasteroids, Prostatitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background α‐1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α‐1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation. Materials and Methods Tissue specimens were obtained from 143 BPH patients who were administered α‐1 blockers up until their operation. Thirty‐three of the patients had also been treated with dutasteride before the procedure. The degree of prostatic inflammation was quantified histologically by the ratio of high endothelial venule (HEV)‐like vessels. We divided this retrospective cohort into α‐1 blocker monotherapy and combination therapy (α‐1 blockers + dutasteride) groups and evaluated clinical parameters of the two groups in relation to the degree of chronic prostatic inflammation. At the same time, we assessed factors exacerbating chronic prostatic inflammation.

Results

Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS total score, voiding subscore, nocturia, intermittency, weak stream, and straining were significantly lower in the combination than the monotherapy group. The duration of α‐1 blockers administration was not correlated with the ratio of HEV‐like vessels, while that of dutasteride was strongly correlated (correlation coefficient = 0.595; p < 0.001). Multiple regression analysis demonstrated that the duration of dutasteride administration was a key factor exacerbating the degree of chronic prostatic inflammation.

Conclusions

The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Hyperplasia5-alpha Reductase InhibitorsAzasteroidsProstatitisAdrenergic alpha-1 Receptor AntagonistsMaleHumansDutasterideAgedRetrospective StudiesMiddle AgedDrug Therapy, CombinationAged, 80 and overProstateInflammation

Stichwörter der Autor:innen

IPSSalpha‐1 blockerchronic prostatic inflammationdihydrotestosteronedutasteridehigh endothelial venule‐like vessel

Substanzen

Dutasteride5-alpha Reductase InhibitorsAzasteroidsAdrenergic alpha-1 Receptor Antagonists

Autor:innen und Institutionen

  • Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
  • Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.

ORCID-Profile: Naoki Terada

Zitieren

APA

Inamura, S., Fukiage, Y., Kobayashi, H., Tsutsumiuchi, M., Seki, M., Taga, M., Fukushima, M., Kobayashi, M., Yokoyama, O., & Terada, N. (2025). Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia. International Journal of Urology. https://doi.org/10.1111/iju.15612

Vancouver

Inamura S, Fukiage Y, Kobayashi H, Tsutsumiuchi M, Seki M, Taga M, et al. Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia. International Journal of Urology. 2025. doi:10.1111/iju.15612

BibTeX
@article{Inamura2025,
  author = {Inamura, So and Fukiage, Yusuke and Kobayashi, Hisato and Tsutsumiuchi, Manami and Seki, Masaya and Taga, Minekatsu and Fukushima, Masato and Kobayashi, Motohiro and Yokoyama, Osamu and Terada, Naoki},
  title = {Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.15612}
}
Kostenlos starten →